Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and key component of the Polycomb repressive complex 2 (PRC2), is frequently overexpressed in prostate cancer and contributes to tumor progression. Here, EZH2 is linked to prostate carcinoma.